Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

Stanley Ly; Vivek Anand; Fouad El-Dana; Khoa Nguyen; Yiming Cai; Shirong Cai; Helen Piwnica-Worms; Debasish Tripathy; Aysegul A Sahin; Michael Andreeff; Venkata Lokesh Battula

doi:10.1136/jitc-2020-001197

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2⁺ breast cancer stem-like cells

Authors

Stanley Ly Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Vivek Anand Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Fouad El-Dana Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Khoa Nguyen Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Yiming Cai Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Shirong Cai Experimental Radiation Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Helen Piwnica-Worms Experimental Radiation Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Debasish Tripathy Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Aysegul A Sahin Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Michael Andreeff Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles
Venkata Lokesh Battula Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USABreast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA PubMed articles Google scholar articles

Citation

Ly S, Anand V, El-Dana F, et al

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2⁺ breast cancer stem-like cells

Journal for ImmunoTherapy of Cancer 2021;9:e001197. doi: 10.1136/jitc-2020-001197

Online issue publication

February 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password